TOKYO (Reuters) - Fujifilm Holdings Corp said it will start phase II clinical trials of its anti-flu drug Avigan for COVID-19 patients in the United States.
The trial will enrol about 50 COVID-19 patients in collaboration with Brigham and Women’s Hospital, Massachusetts General Hospital, and the University of Massachusetts Medical School, Fujifilm said on Thursday.
On March 31, Fujifilm announced the start of a phase III clinical trial of Avigan for COVID-19 patients in Japan.
Reporting by Rocky Swift; Editing by Himani Sarkar
Our Standards: The Thomson Reuters Trust Principles.